You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾誠健華(09969.HK)公佈中期業績 研發開支大增144% 現金結餘達44.1億元
格隆匯 08-21 20:46

格隆匯8月21日丨諾誠健華(09969.HK)公告,截至2020年6月30日止6個月,公司收入74.8萬元人民幣,同比增長26%;公司擁有人應占虧損4.07億元,上年同期虧損3.21億元;每股虧損0.53元。

收益增加主要歸因於由南京諾誠健華向第三方提供的研發服務。預期公司的在研候選藥物(包括奧布替尼)於不久將來在獲批後推出市場後,公司的收益來源將更為多元化。

研發成本由上年同期的人民幣9480萬元增加144%至人民幣2.31億元,該增加主要是由於公司擴展臨牀試驗及股份支付增加所致。

截至2020年6月30日,公司有流動資產淨額人民幣44.35億元,主要歸因於公司的現金及銀行結餘人民幣44.1億元及按公允價值計入損益的投資人民幣3010萬元,部分被其他應付款項及應計費用人民幣5050萬元所抵銷。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account